Percheron Therapeutics has announced that it will investigate avicursen (ATL1102) in other indications besides Duchenne muscular dystrophy (DMD) following disappointing Phase IIb results last month.

DMD occurs in approximately one in every 3,500 male births. Credit: Dan76 / Shutterstock. Percheron Therapeutics has announced that it will investigate avicursen (ATL1102) in other indications besides ...

Percheron Therapeutics board addresses shareholders following failed phase 2b trial EBR’s US FDA manufacturing pre-approval inspection scheduled to start January 14 as share price rockets Regis ...

Percheron Therapeutics (AU:PER) has released an update. Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Percheron Therapeutics has reported a significant change in its substantial shareholding, as Platinum Investment ...

Percheron Therapeutics (ASX: PER), an international biotechnology company, unveiled the topline results from its six-month phase 2b trial of avicursen (ATL1102) in non-ambulant boys with Duchenne ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Percheron Therapeutics Limited announced the cessation of certain securities as of December 20, 2024 ...

The incoming president promised “tariffs all the way” unless Europe bought more U.S. oil and gas. European officials have no clear strategy for avoiding a trade war. By Jim Tankersley Jenny ...

Get global perspectives and insights from CEOs on the biggest stories in business. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Percheron Therapeutics Limited has announced that Powerhouse Ventures Limited has become a substantial holder in the company, acquiring a 5.058% voting power through the purchase of 55,000,000 ...